The importance of bio-markers in diagnostic and evaluation of prognosis for patients with cardiovascular and pulmonary pathology


Cite item

Full Text

Abstract

In modern conditions the multimorbidity is an integral trait of chronic obstructive disease of lungs. The cardiovascular diseases are found more frequently in patients with chronic obstructive disease of lungs than in total population. According to modern concepts, systemic inflammation related to unbalance of pro- and anti-inflammatory cytokines is important in pathogenesis of chronic obstructive disease of lungs. This can be a cause of development of extra pulmonary manifestation of chronic obstructive disease of lungs and comorbide diseases and especially cardiovascular diseases. The article considers studies covering major bio-markers being additional instrument to evaluate risk and prognosis in patients with concomitant diseases under chronic obstructive disease of lungs.

About the authors

Elena A. Demochko

“The polyclinic №1” of the executive office of President of the Russian Federation

Email: demochko@mail.ru
therapeutist 119002, Moscow, Russia

L. O Minushkina

“The teaching and research medical center” of the executive office of President of the Russian Federation

121359, Moscow, Russia

References

  1. WHO World Health Organization Website. Chronic obstructive pulmonary disease. Available at: http://www.who.int/respiratory/copd/en/ по состоянию на 23 марта 2014 г.
  2. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available at: http://www.goldcopd.org/.
  3. Agusti A., Calverley P.M., Celli B., Coxson H.O., Edwards L.D., Lomas D.A. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
  4. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28: 1245-57.
  5. Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 204-12.
  6. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165-85.
  7. Johnston A.K., Mannino D.M., Hagan G.W., Davis K.J., Kiri V.A. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008; 63: 599-605.
  8. Lange P., Mogelvang R., Marott J.L., Vestbo J., Jensen J.S. Cardiovascular morbidity in COPD: A study of the general population. COPD. 2010; 7(1): 5-10.
  9. Sin D.D., Wu L., Man S.F.P. The relationship between reduced lung function and cardiovascular mortality: a populationbased study and a systematic review of the literature. Chest. 2005; 127 (6): 1952-9.
  10. Rutten F.H., Moons K.G., Cramer M.J. et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. Br. Med. J. 2005; 331(7529): 1379.
  11. Boudestein L.C.M., Rutten F.H., Cramer M.J., Lammers J.W.J., Hoes A.W. The impact of concurent heart failure on prognosis in patients with chronic bstructive pulmonary disease. Eur. J. Heart. Fail. 2009; 11: 1182-8.
  12. Lainscak M., Hodoscek L.M., Diingen H.D. et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien. Klin. Wochenschr. 2009; 121(9-10): 309-13.
  13. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations andmortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166 (3): 333-9.
  14. Holguin F., Folch E., Redd S.C., Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005; 128: 2005-11.
  15. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005; 128: 2640-6.
  16. McGarvey L.P., John M., Anderson J.A., Zvarich M., Wise R.A. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007; 62: 411-5.
  17. Han M.K., Agusti A., Calverley P.M. et al. COPD phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598-604.
  18. Burgel P.R., Paillasseur J.L, Caillaud D. et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 2010; 36: 531-9.
  19. Lacoma A., Prat C., Andreo F., Dominguez J., Biomarkers in the management of COPD. Eur. Respir. Rev. 2009; 18: 96-104.
  20. Pepys M.B., Hirschfield G.M. C-reactiveprotein: a critical update. J. Clin. Invest. 2003; 111: 1805-12.
  21. Devaraj S., Xu D.Y., Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003; 107(3): 398-404.
  22. Singh P., Hoffmann M., Wolk R. et al. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2007; 27(9): 302-7.
  23. Dahl M., Vestbo J., Lange P. et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 250-5.
  24. Aksu F., Capan N., Aksu K., Ofluoglu R., Canbakan S., Yavuz B. et al. C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. J. Thorac. Dis. 2013; 5(4): 414-21.
  25. Man S.F., Connett J.E., Anthonisen N.R. et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61: 849-53.
  26. de Torres J.P., Pinto-Plata V., Casanova C. et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008; 133: 1336-43.
  27. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2012; 186: 982-8.
  28. Gong H.Jr., Sioutas C., Linn W.S. Controlled exposures of healthy and asthmatic volunteers to concentrated ambient particles in metropolitan. Res. Rep. Health Eff. Inst. 2003; 118: 1-36.
  29. Valvi D., Mannino D.M., Muellerova H., Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7: 173-82.
  30. Guggilam A., Cardinale J.P., Mariappan N. et al. Central TNF inhibition results in attenuated neurohumoral excitation in heart failure: a role for superoxide and nitric oxide. J. Basic Res. Cardiol. 2011; 106 (2) : 273-86.
  31. Калюжин В.В., Тепляков А.Т., Вечерский Ю.Ю., Резанцева Н.В., Хлапов А.П. Патогенез хронической сердечной недостаточности: изменение доминирующей парадигмы. Бюллетень сибирской медицины. 2007; 4: 71-9.
  32. Симбирцев А.С. Цитокины: классификация и биологические функции. Цитокины и воспаление. 2004; 3(2): 16-22.
  33. Васюк Ю.А., Дударенко О.П., Ющук Е.Н., Школьник Е.Л., Серова М.К. Цитокиновая модель патогенеза хронической сердечной недостаточности и возможности нового терапевтического подхода в лечении декомпенсированных больных. Рациональная фармакотерапия в кардиологии. 2006; 4: 63-70.
  34. Bozkurt B., Mann D.L., Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010; 15 (4): 331-41.
  35. Hedayat M. et al. Proinflammatory cytokines in heart failure: doubleedged swords. Heart Fail Rev. 2010; 15 (6): 543-62.
  36. Волкова С.Ю. Диагностические возможности ряда нейрогуморальных систем в определении систолической дисфункции левого желудочка у больных ИБС с сердечной недостаточностью. Сердечная недостаточность. 2008; 1 (45): 25-30.
  37. Boffa G.M. et al. Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. J. Cardiovasc. Med. 2009; 10 (10): 758-64.
  38. Barczyk A. et al. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2006; 117: 1484-92.
  39. Plenz G., Song Z.F., Tjan T.D. et al. Activation of the cardiac interlrleukin-6 system in advanced heart failure. Eur. J. Heart Fail. 2001; 3: 415-21.
  40. Stolz D., Christ-Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007; 131: 9-19.
  41. Becker K.L., Snider R., Nylen E.S. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit. Care Med. 2008; 36: 941-52.
  42. Perren A., Cerutti B., Lepori M. et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection. 2008; 36: 163-6.
  43. Stolz D., Breidthardt T., Christ-Crain M. et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008; 133: 1088-94.
  44. Berdowska A., Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J. Clin. Pharm. Ther. 2001; 26: 319-29.
  45. Takabatake N., Sata M., Abe S. et al. Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD. Respir. Med. 2005; 99: 485-92.
  46. Radsak M.P., Taube C., Haselmayer P. et al. Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease. Clin. Dev. Immunol. 2007; 2007: 52040.
  47. Prat C., Lacoma A., Dominguez J. et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J. Infect. 2007; 55: 400-7.
  48. Muller B., Suess E., Schuetz P. et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J. Intern. Med. 2006; 260: 568-76.
  49. Portillo K.L., Martinez-Rivera C., Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int. J. Clin. Pract. 2013; 67(6): 558-65.
  50. Nowinski A., Kaminski D., Korzybski D., Stoklosa A., Gorecka D. The impact of comorbidities on the length of hospital treatment in patients with chronic obstructive pulmonary disease. Pneumonol. Alergol. Pol. 2011; 79: 388-96.
  51. Cote C., Zilberberg M.D., Mody S.H., Dordelly L.J., Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur. Respir. J. 2007; 29: 923-9.
  52. Gan W.O., Man S.F.P. et al. Association between chronic obstructive pulmonary disease and systemic inflammation a systemic review and a meta-analysis. Thorax. 2004; 59: 574-80.
  53. Attaran D. et al. Anemia in COPD patients and its relation to serum levels of erythropoietin. Tanaffos. 2009; 8 (2): 11-6.
  54. Pat G., Goring C., Goring S.M. Gender and the diagnosis, management, and surveillance of chronic obstructive pulmonary disease. Proc. Am. Thorac. 2007; 4: 24-8.
  55. Chambellan et al. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2006; 129 (3) : 831.
  56. Agusti A.G., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21(2): 347-60.
  57. John M., Hoernig S., Doehner W., Okonko D.D., Witt C., Anker S.D. Anemia and inflammation in COPD. Chest. 2005; 127(3): 825-9.
  58. O’Meara E., Clayton T., McEntegart M.B. et al. CHARM Committees and Investigators Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM). Program. Circulation. 2006; 113: 986-94.
  59. Akram K., Pearlman B.L. Congestive heart failure-related anemia and a role for erythropoietin. Int. J. Cardiol. 2007; 117: 296-305.
  60. Guo L., Wang A.H., Sun Y.L., Lv L., Xu C.E. Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia. Exp. Ther. Med. 2013; 6(5): 1327-31.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies